Abstract | PURPOSE: METHODS: Thirty eyes of 27 patients with progressive corneal neovascularisation (not responding to conventional anti-inflammatory treatment) due to different underlying corneal diseases received topical bevacizumab ( Avastin) eye drops (5 mg/ml Bevacizumab) for 0.5-12 months (five times/day on average). At each visit, a routine Snellen visual acuity assessment was performed, followed by ophthalmic examination including fluorescein staining. Changes of corneal neovascularization and vessel diameter were assessed using morphometry of standardized digital corneal photographs. RESULTS: Five patients (five eyes) developed new corneal epithelial defects during topical bevacizumab treatment. In 22 patients, no new epithelial defects were observed. None of the 27 patients complained about any drug-related ocular or systemic adverse events during follow-up. No allergic reactions were observed. Corneal photographs of 21 eyes (19 patients) could be assessed. The mean reduction in vascularized area during treatment was 61%. The mean reduction in vessel diameter under topical Avastin therapy was 24%. CONCLUSIONS:
|
Authors | Yanyan Koenig, Felix Bock, Folkert Horn, Friedrich Kruse, Katja Straub, Claus Cursiefen |
Journal | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
(Graefes Arch Clin Exp Ophthalmol)
Vol. 247
Issue 10
Pg. 1375-82
(Oct 2009)
ISSN: 1435-702X [Electronic] Germany |
PMID | 19415316
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ophthalmic Solutions
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Antibodies, Monoclonal
(administration & dosage, analysis)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Blood Vessels
(drug effects, pathology)
- Cornea
(blood supply)
- Corneal Diseases
(complications)
- Corneal Neovascularization
(drug therapy, etiology, pathology, surgery)
- Drug Administration Schedule
- Drug Therapy
- Epithelium, Corneal
(drug effects, pathology)
- Female
- Follow-Up Studies
- Humans
- Limbus Corneae
(cytology)
- Male
- Middle Aged
- Ophthalmic Solutions
- Postoperative Care
- Stem Cell Transplantation
- Time Factors
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|